News

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
PMLive1d
Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...
Fierce Pharma4d
Madrigal touts biomarker data in key MASH population as it works to grow Rezdiffra's reach
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
MyChesCo on MSN4d
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Nasdaq6d
Madrigal Pharmaceuticals Reports Positive Two-Year Results for Rezdiffra in Phase 3 MAESTRO-NAFLD-1 Trial for MASH Cirrhosis
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...